News From Our Partners

Discontinuation of Gardasil 9 Single Dose Vials

Posted 03/18/19

Merck will be discontinuing the 10-pack of single-dose vials of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and will solely offer the 10-pack of single-dose prefilled syringes. Effective March 18, 2019, customers will no longer be able to order the 10-pack of single-dose vials for GARDASIL 9 via However, the vial image will be available to order via the Merck Vaccine Customer Center (MVCC). Vials will also continue to be available via Physicians Distributors and Wholesalers.

When you open the product catalog on, you will still see the GARDASIL 9 10-pack of single-dose vials in the product catalog but will be unable to order it. The following information will be displayed in the product catalog for the GARDASIL 9 10-pack of single dose vials: “Syringe image is available to order. Please call the Merck Vaccine Customer Center (877.VAX.MERCK) if you have any questions about vials.”

MenB Outbreak Declared at Columbia University’s School of International and Public Affairs

Posted 02/15/19

Pfizer Press Release

Important Update: MenB Case at Rutgers University

Posted 02/15/19

Pfizer Press Release

FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

Posted 01/25/19

Sanofi Press Release

Exciting Update on Adacel® Vaccine Usage

Posted 01/23/19

Previously, all Tdap vaccines were licensed as a single dose. We are excited to inform you that as of January 11, 2019, Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) is the first and ONLY Tdap vaccine approved for repeat vaccination.1

Additional important information is provided below:

· Adacel vaccine is now approved for repeat vaccination 8 years or more after the initial dose1

· Immunity acquired from vaccination can wane; giving a second dose can help to maintain pertussis protection2

· Adacel vaccine is the first and ONLY Tdap vaccine in a prefilled syringe manufactured without natural rubber latex

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise1

Please see full Important Safety Information below.

The NDC number for Adacel vaccine in both the prefilled syringe presentation made without natural rubber latex and the unit-dose vial presentation made without natural rubber latex:

Under your Main Street Vaccines contract, the price will not change.


Adacel vaccine is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.


Adacel vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any other tetanus toxoid‐, diphtheria toxoid‐, or pertussis antigen‐containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen‐containing vaccine with no other identifiable cause.

For one presentation of Adacel, the tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex‐sensitive individuals. The vial stopper is not made with natural rubber latex.

If Guillain‐Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid‐containing vaccine, if progressive or unstable neurologic disorders exist, or if adverse events have occurred in temporal relation to receipt of pertussis antigen‐containing vaccine, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.

Persons who experienced an Arthus‐type hypersensitivity reaction following a prior dose of tetanus toxoid‐containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid‐containing vaccine.

Syncope (fainting) can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

Please see the full Prescribing Information.

Please reach out to Sanofi Pasteur at 1-800-VACCINE for any product questions.

References: 1. Adacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur

Inc. 2. Centers for Disease Control and Prevention. Prevention of Pertussis, Tetanus,

and Diphtheria with Vaccines in the United States: Recommendations of the Advisory

Committee on Immunization Practices (ACIP). MMWR. 2018;67(2):1-46.

SAUS.ADAC.18.12.6981 1/19

DPH Statement on Confirmed Case of Meningococcal Meningitis Type B in One Student at Central Connecticut State University (CCSU)

Posted 12/07/18

A case of Serogroup B Meningococcal disease (MenB) was confirmed at Central Connecticut State University. The attached PDF summarizes the details of the MenB case.

MenB Case at Syracuse University

Posted 10/11/18

A case of Serogroup B Meningococcal disease (MenB) was confirmed at Syracuse University on October 5, 2018. The attached PDF summarizes the details of the MenB case.

Pfizer Price Notification

Posted 11/09/17

Please click here for information on Pfizer pricing.

Six-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress

Posted 10/11/17

KENILWORTH, N.J.—(BUSINESS WIRE)— Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced results from final analyses of the pivotal Phase III efficacy, immunogenicity, and safety clinical trial for GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). The data, which showed sustained efficacy for up to six years in the per protocol population, were presented during an oral session at the European Research Organization on Genital Infection and Neoplasia(EUROGIN) congress in Amsterdam, Netherlands.

Please click here for the full report.

Pnemovax 23 Dosing Information

Posted 10/04/17
Please click here for the latest Pnemovax 23 dosing information for patients over and under 65.

Merck Warehouse Locations Are Changing

Posted 03/22/17

Dear Health Care Professional:

Merck is continually looking for ways to improve our service to you and, as a result, will be changing the warehouse locations in the United States from where we store, pack, and ship your vaccine orders. This change will be effective Monday, May 1, 2017, and will provide added flexibility and efficiency as we strive to meet our shipping commitments to you.

While we expect this process to go smoothly, there will be a temporary disruption to our shipping schedule as we complete the move to the new warehouses. On Wednesday, April 26, and Thursday, April 27, Merck will only be shipping certain vaccines as outlined below. Please note that you can continue to place orders for all Merck vaccines during this time. We expect normal shipping (from the new warehouses) to resume on Monday, May 1. Additionally, United Parcel Service (UPS) will continue to deliver your orders.

Vaccines that will ship during warehouse transition:

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)
  • ProQuad® (Measles, Mumps, Rubella, and Varicella Virus Vaccine Live)
  • VARIVAX® (Varicella Virus Vaccine Live)
  • ZOSTAVAX® (Zoster Vaccine Live)

All other Merck vaccines will not ship during the warehouse transition.

Please consider adjusting your ordering needs, as appropriate, to ensure you have adequate vaccine inventory on hand during this brief transition.

If you have questions, please contact your Merck Account Representative or call the Merck Vaccine Customer Center at 877-VAX-MERCK (877-829-6372), Monday through Friday, 8:00 AM to 7:00 PM, ET.

We appreciate your business and thank you for your understanding as we look to serve you better.


Colleen McGuffin
Vice President, US Commercial Operations
Merck & Co., Inc.

Important Information About the Influenza VIS Sheet

Posted 08/24/16

Recently, the CDC announced they are no longer issuing an annual update to the influenza vaccine information sheet (VIS). As a result, the CDC has advised health care providers to use the influenza VIS sheet that was issued on August 7, 2015. Please click here to access that VIS sheet.

Zostavax® Price Action

Posted 07/05/16

Merck has announced that there will be a 4.8% increase in the cost of Zostavax® effective July 5, 2016 for Main Street Members. New prices will be posted here.

FluMist® Use Discouraged by CDC

Posted 06/24/16

AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist® Quadrivalent Live Attenuated Influenza Vaccine (FluMist Quadrivalent) in the US for the 2016-2017 influenza season. The updated guidance states the vaccine should not be used in any setting, based on CDC vaccine effectiveness data from the last three influenza seasons in the US, which indicated FluMist Quadrivalent did not demonstrate statistically significant effectiveness in children 2-17 years of age.

The US CDC effectiveness data for 2015-2016 season contrast with studies by AstraZeneca as well as preliminary independent findings by public health authorities in other countries. These findings demonstrate FluMist Quadrivalent was 46-58% effective overall against the circulating influenza strains during the 2015-2016 season. As influenza vaccine effectiveness varies from season to season, it is evaluated in annual observational studies. The CDC states that when there is a good match between the strains in the vaccine and those that circulate during the influenza season, vaccines are typically 50-60% effective.3 AstraZeneca is working with the CDC to better understand its data to help ensure eligible patients continue to receive the vaccine in future seasons in the US.

Please click here to see the original announcement on the AstraZeneca/MedImmune website.

Order Merck Vaccines Through a Prime Distributor

Posted 06/24/16

Effective July 1, 2016, Merck is giving members of a Merck-contracted Physician Organization the option of ordering Merck Vaccines directly through Merck and, now, through a Merck Vaccines Prime Distributor (“Prime Distributor”). This change will allow you to now purchase Merck Vaccines at contracted prices directly from Merck or through a Prime Distributor (a list of current Prime Distributors can be found at Please check regularly as the list is subject to change).

Prime Distributors must provide Merck Vaccines to eligible members at a price no higher than the Merck contracted price. Prime Distributors may apply additional charges to the invoice, such as, but not limited to, charges related to minimum order quantities, taxes, shipping, etc. The terms of sale for the Prime Distributors could be different from Merck’s terms of sale and should be reviewed prior to placing any orders. Please note that, if purchasing through a Prime Distributor, you will not be eligible for Merck’s prompt pay discount but could be eligible for the Prime Distributor’s payment terms. It is your responsibility to research the Prime Distributor’s terms prior to placing your order.

Your pricing under your Physician Organization agreement will not be available from eligible Prime Distributors until July 1, 2016. The Prime Distributors shall be subject to the Merck terms and conditions of sale in effect at the time of purchase. It is important that, if ordering through a Prime Distributor, you first confirm that the Prime Distributor is authorized through Merck. Secondly, you should confirm your pricing with the Prime Distributor prior to placing your first order to ensure that you are properly set up with the Prime Distributor and are receiving contracted pricing. If you choose to purchase through a Prime Distributor but you do not have an account with that Prime Distributor, you must first initiate the setup of your account with the Prime Distributor and receive confirmation prior to any purchases. You may still order directly through Merck as long as you have an active Merck Account.

For further guidance, please contact your Physician Organization or your Merck Representative. We are excited to be able to offer you this option and look forward to continued success.

Michele Taylor
Director, US National Customer Operations & Partnerships

Connect with us on: